S Proud To Announce That Dosing Has Commenced In The Phase 1 First Human Trial For Kio 301 This Representsa Remarkable Development Treatment Of People With Rare Inherited Condition News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health: "Clinical research is not about just testing something in a group of trial participants. It is about creating measurable improvements for people's health and wellbeing that will ....

South Australia , New South Wales , Greg Plunkett , Brianm Strem , Nicole Kanellopoulos Remy , Robert Casson , Kiora Pharmaceuticals , Kiora Pharmaceuticals Inc , Contract Research Organisation , Putting Australian , Royal Adelaide Hospital , Retinitis Pigmentosa , Royal Adelaide , Professor Robert Casson , Chief Executive Officer , Remy Arena , Ocular Presentation , Rheumatoid Arthritis , Dihydroorotate Dehydrogenase , Putting Australian Clinical Research On The Map Globally , Omes The Ground Breaking First In Human Clinical Trial For Kio 301 Melbourne , Feb 15 , 023 Prnewswire In Collaboration With Us Based Kiora Pharmaceuticals , Nc Nasdaq Kprx And The Royal Adelaide Hospital , Eading Australian Cro , S Proud To Announce That Dosing Has Commenced In The Phase 1 First Human Trial For Kio 301 This Representsa Remarkable Development Treatment Of People With Rare Inherited Condition ,